New research: Longer telomeres cure fatal disease

Telomerase – the enzyme activated by the active ingredient in One Truth 818 skin serum – has been used by scientists to cure a potentially fatal disease that’s baffled the medical world for decades.

Study co-author Maria A. Blasco

Pulmonary Fibrosis in mice – a deadly lung disease for humans – has been cured by scientists in the the Telomere and Telomerase Group at the Spanish National Cancer Research Centre, using gene therapy that lengthens the telomeres.

It is “proof of concept that telomerase activation represents an effective treatment against pulmonary fibrosis,” the authors write in their study in the journal eLife. 

This will come as no surprise to Dr Bill Andrews PhD, the molecular biologist who discovered the most powerful telomerase-activating compound so far known to science. The TAM-818 molecule is the active ingredient in the new One Truth 818 skin serum. Dr Andrews has long taught that lengthening telomeres is one of the keys to preventing aging, and the diseases that come with the breakdown of our body’s cells.

“The most relevant aspect of our work is that it suggests a potentially viable and effective solution to a real clinical problem, pulmonary fibrosis, for which there is still no treatment,” says Paula Martínez, co-author of the Spanish study. “The only approved treatments for pulmonary fibrosis up-to-date have no curative effects, as they target a symptom and not the cause of fibrosis. Our therapy is based on correcting the molecular cause of pulmonary fibrosis in patients with short telomeres, introducing into the cells of damaged lung tissue the only enzyme capable of lengthening telomeres, telomerase.”

Telomeres are protein structures located at the ends of each chromosome; like caps, they protect the integrity of the chromosome when the cell divides. But telomeres only fulfill their protective function if they are long enough; when they shorten too much, the damaged cells cease to divide preventing tissue regeneration. Short telomeres are associated with aging -as age increases, cells accumulate more divisions and more telomeric shortening- and also with several diseases.

Patients with pulmonary fibrosis have short telomeres whether the disease is hereditary -it runs into the family- or not. The most likely explanation is that when the telomeres become too short, the damaged cell activates a ‘repair program’ that induces scar formation that leads to fibrosis.

The Spanish study shows that activating the telomerase enzyme to lengthen the telomeres in the lung tissue may constitute an effective therapeutic strategy to treat human pulmonary fibrosis. It has proven so in mice. Only three weeks after treatment, the sick animals “showed improved lung function and less inflammation and fibrosis” -the authors write in eLife-; two months after the treatment, the fibrosis had “improved or disappeared”.

One Truth 818 skin serum is the only skin cream in the world that contains the TAM-818 ‘telomerase activating molecule’. 

See Case Studies here. 

Order One Truth 818 here – free shipping worldwide.